Lexeo Therapeutics Inc (LXEO)

Currency in USD
4.43
-0.02(-0.45%)
Real-time Data·
LXEO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 10 days
LXEO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.354.52
52 wk Range
1.4512.76
Key Statistics
Prev. Close
4.45
Open
4.45
Day's Range
4.35-4.52
52 wk Range
1.45-12.76
Volume
52.77K
Average Volume (3m)
634.57K
1-Year Change
-62.03%
Book Value / Share
2.65
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LXEO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
18.00
Upside
+306.32%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings upwards for the upcoming period

Lexeo Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Lexeo Therapeutics Inc Company Profile

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.

Lexeo Therapeutics Inc SWOT Analysis


Gene Therapy Pionee
Lexeo Therapeutics leads in rare cardiac diseases and Alzheimer's with innovative AAVrh10-based gene therapies, targeting high-impact medical needs
Pipeline Potential
Explore Lexeo's three key programs: LX2006 for Friedreich's Ataxia, LX2020 for PKP2-ACM, and LX1001 for Alzheimer's, with crucial data expected in 2024
Regulatory Landscape
Learn how Lexeo navigates a favorable FDA environment, potentially streamlining development through single-arm trials and flexible approval pathways
Market Outlook
Analyst price targets range from $24 to $28, reflecting optimism despite current market volatility and the speculative nature of gene therapy investments
Read full SWOT analysis

Compare LXEO to Peers and Sector

Metrics to compare
LXEO
Peers
Sector
Relationship
P/E Ratio
−2.2x−3.4x−0.5x
PEG Ratio
−0.050.000.00
Price/Book
2.7x2.7x2.6x
Price / LTM Sales
-151.9x3.3x
Upside (Analyst Target)
329.2%200.8%43.4%
Fair Value Upside
Unlock6.0%7.1%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 18.00
(+306.32% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.99 / -0.89
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

LXEO Income Statement

People Also Watch

5.09
REPL
-7.18%
47.21
BMNR
+14.37%
18.32
SRPT
+1.98%
2.57
INMB
-8.06%
11.9730
INKT
-5.43%

FAQ

What Stock Exchange Does Lexeo Therapeutics Trade On?

Lexeo Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Lexeo Therapeutics?

The stock symbol for Lexeo Therapeutics is "LXEO."

What Is the Lexeo Therapeutics Market Cap?

As of today, Lexeo Therapeutics market cap is 240.29M.

What Is Lexeo Therapeutics's Earnings Per Share (TTM)?

The Lexeo Therapeutics EPS (TTM) is -3.31.

When Is the Next Lexeo Therapeutics Earnings Date?

Lexeo Therapeutics will release its next earnings report on 17 Aug 2025.

From a Technical Analysis Perspective, Is LXEO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Lexeo Therapeutics Stock Split?

Lexeo Therapeutics has split 0 times.

How Many Employees Does Lexeo Therapeutics Have?

Lexeo Therapeutics has 75 employees.

What is the current trading status of Lexeo Therapeutics (LXEO)?

As of 08 Aug 2025, Lexeo Therapeutics (LXEO) is trading at a price of 4.43, with a previous close of 4.45. The stock has fluctuated within a day range of 4.35 to 4.52, while its 52-week range spans from 1.45 to 12.76.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.